Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 11/20 | 0.46 |
| ▸ | CTSS | P25774 | 8/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393366 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL20783244 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| Hydrochloric Acid SCHEMBL17686459 | 0.98 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| Hydrochloric Acid SCHEMBL14471495 | 0.98 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL1167043 | 0.91 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL1770995 | 0.91 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL8238351 | 0.91 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| Hydrochloric Acid SCHEMBL1770994 | 0.89 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| Hydrochloric Acid SCHEMBL1770997 | 0.89 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL7494252 | 0.88 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346578-A1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | AVEDRO INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250283066-A1 | METHODS AND COMPOSITIONS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-09-11 | — | — | US | disclosed |
| US-12344598-B2 | Bis(diazirine) derivatives as photo-crosslinker for treating corneal ectatic disorders | AVEDRO, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-12286657-B2 | Methods and compositions | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-04-29 | — | — | US | disclosed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| EP-3914586-B1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | AVEDRO INC (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| US-20220106298-A1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | AVEDRO, INC. | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346578-A1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | SYMPK, DSG1, JUP | CYP1A2 964/4885CYP2C9 4096/4885CYP2C19 2260/4885 |
| US-12286657-B2 | Methods and compositions | TRMT1, TARBP1, RNGTT | CYP1A2 4074/4885CYP2C9 3167/4885CYP2C19 4418/4885 |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | CYP1A2 2245/4885CYP2C9 3379/4885CYP2C19 1767/4885 |
| US-20250283066-A1 | METHODS AND COMPOSITIONS | TRMT1, TARBP1, RNGTT | CYP1A2 4074/4885CYP2C9 3167/4885CYP2C19 4418/4885 |
| US-20220106298-A1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | PSEN1, DSG1, GRIK1 | CYP1A2 1347/4885CYP2C9 4173/4885CYP2C19 2729/4885 |
| US-12344598-B2 | Bis(diazirine) derivatives as photo-crosslinker for treating corneal ectatic disorders | PSEN1, GRIK1, DSG1 | CYP1A2 1368/4885CYP2C9 4164/4885CYP2C19 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.